Biotechnology: Biological Products (No Diagnostic Substances)

Clinical TrialMay 21, 2026, 04:06 PM

Revolution Medicines to Discuss Positive Phase 3 Daraxonrasib Results

AI Summary

Revolution Medicines announced that its senior management team will host a webcast on Sunday, May 31, at 7:00 pm ET. The webcast will discuss positive results from the Phase 3 RASolute 302 clinical trial, which evaluated daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). These data are scheduled for presentation during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Highlights

Revolution Medicines to host webcast on May 31 at 7:00 pm ET.
Webcast will discuss positive Phase 3 RASolute 302 clinical trial results.
Trial evaluated daraxonrasib for metastatic pancreatic ductal adenocarcinoma (PDAC).
Data to be presented at the 2026 ASCO Annual Meeting Plenary Session.
Company is a late-stage clinical oncology firm developing RAS-addicted cancer therapies.
Pipeline includes daraxonrasib, elironrasib, zoldonrasib, and RMC-5127.

View SEC Filing

RVMD

Biotechnology: Biological Products (No Diagnostic Substances)

Revolution Medicines, Inc.

Price Impact